Key terms
About ACET
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACET news
Apr 02
6:30am ET
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
Mar 21
9:05am ET
Adicet Bio (ACET) Receives a New Rating from Truist Financial
Mar 20
12:26pm ET
Adicet Bio: A Strong Buy on Robust Financials and Promising Clinical Trials
Mar 20
10:55am ET
Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing
Mar 20
7:25am ET
Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification
Mar 20
5:56am ET
Buy Recommendation for Adicet Bio Amid Promising Autoimmune and Cancer Therapy Developments
Mar 20
12:25am ET
JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)
Mar 19
4:13pm ET
Adicet Bio reports Q4 EPS (69c), consensus (69c)
Feb 13
2:02pm ET
Adicet upgraded to Buy on cell therapy potential at JonesResearch
Feb 13
1:56pm ET
Adicet Bio upgraded to Buy from Hold at JonesResearch
Feb 02
9:34am ET
Adicet Bio price target lowered to $10 from $26 at H.C. Wainwright
Jan 25
4:36am ET
Adicet Bio Announces Offering Pricing and Cash Position
Jan 25
4:36am ET
Adicet Bio Launches Public Stock and Warrant Offering
Jan 23
6:14am ET
Adicet Bio 27.05M share Spot Secondary priced at $2.40
Jan 22
4:30pm ET
Adicet Bio announces common stock offering, no amount given
Jan 09
4:26pm ET
JMP Securities Sticks to Their Hold Rating for Adicet Bio (ACET)
Jan 07
5:28am ET
Adicet Bio (ACET) Gets a Buy from BTIG
Jan 05
7:29am ET
Adicet Bio price target lowered to $19 from $21 at Canaccord
Jan 04
12:25pm ET
Buy Rating on Adicet Bio Backed by Strong Clinical Data and Strategic Focus on MCL
No recent press releases are available for ACET
ACET Financials
Key terms
Ad Feedback
ACET Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACET Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range